Chronic treatment with an adenosine A2A receptor antagonist (istradefylline) reversed memory deficits caused by chronic cannabinoid exposure in rats, without changing receptor levels in the brain.
Neuropharmacologists, clinicians managing cannabinoid therapy side effects, and drug repurposing researchers.
Memory deficits reversed
What the researchers found
Chronic istradefylline (3 mg/kg/28 days) reversed memory deficits (Novel Object Recognition Test) caused by chronic WIN 55,212-2 (1 mg/kg/28 days). In hippocampal slices, the A2A antagonist partially rescued cannabinoid-impaired long-term potentiation. Neither chronic treatment affected A2A or CB1 receptor binding in hippocampus or prefrontal cortex.
Why it matters
Patients on long-term cannabinoid therapies (e.g., for epilepsy, pain, spasticity) may experience cognitive side effects. If A2A antagonists can reverse these without affecting cannabinoid therapeutic efficacy, they could be valuable co-treatments.
The numbers in context
Istradefylline 3 mg/kg/day for 28 days reversed memory deficits. WIN 55,212-2 300 nM impaired hippocampal LTP. SCH 58261 100 nM partially rescued LTP. No changes in A2A or CB1 receptor binding after chronic treatment.
How the study worked
Chronic 28-day treatment in rats with behavioral memory testing (NORT), electrophysiological hippocampal recordings (LTP), and receptor binding assays for A2A and CB1 receptors in hippocampus and PFC.
What this study cannot tell us
Rat model using a synthetic cannabinoid (WIN 55,212-2), not THC or CBD. LTP rescue was partial, not complete. Behavioral assessment limited to object recognition. 28-day treatment may not predict longer-term outcomes.
How to read the evidence
Preliminary: rat study with a synthetic cannabinoid, though using an already-approved drug.
When this study was published
Published in 2019.
The bigger picture
Istradefylline is already FDA-approved for Parkinson's disease. Repurposing it to mitigate cannabinoid cognitive side effects would be faster than developing a new drug, and this study provides the rationale.
Questions still open
- Would istradefylline prevent THC or CBD cognitive side effects in humans? Does A2A antagonism interfere with cannabinoid therapeutic effects (seizure control, pain relief)?
Common questions
Can memory problems from cannabinoids be reversed?
How does this work?
Read the original research
Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism.
Neuropharmacology, 155, 10-21
Citation
Mouro, Francisco M; Köfalvi, Attila; André, Luís A; Baqi, Younis; Müller, Christa E; Ribeiro, Joaquim A; Sebastião, Ana M. (2019). Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism.. Neuropharmacology, 155, 10-21. https://doi.org/10.1016/j.neuropharm.2019.05.003
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)